Sònia Guedan

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer — Spain

Medicine · Health Sciences

28h-index6.2kcitations198works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(165), Viral Infectious Diseases and Gene Expression in Insects(48), Virus-based gene therapy research(39), Immune Cell Function and Interaction(31), Immunotherapy and Immune Responses(18)

Publications198 total

Abstract C006: In vivo CRISPR-screen identifies determinants of early CAR-T cell dysfunction in solid tumors
Cancer Immunology Research·2026
Abstract C007: A versatile microRNA-based platform for activation-dependent regulation of armored CAR T cell payloads
Cancer Immunology Research·2026
Figure S11 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S6 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S4 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S8 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S9 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Table S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S3 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Table S1 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S7 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S5 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S10 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S1 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Abstract 5867: Uncovering T-cell receptor clones and immunogenic targets in HER2DX-defined HER2-positive breast cancer
Cancer Research·2025
Lymph-Node Inspired Hydrogels Enhance CAR Expression and Proliferation of CAR T Cells
ACS Applied Materials & Interfaces·2025· 3 citedOpen Access
Unlocking the potential of engineered immune cell therapy for solid tumors
Nature Communications·2025· 17 citedOpen Access
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer
UNC Libraries·2025Open Access
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer
ESMO Open·2025· 3 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Carl H. June(19), Shannon E. McGettigan(10), John Scholler(10), Ramón Alemany(10), Avery D. Posey(9), Alena Gros(8), Alba Rodríguez-García(7), Manel Cascalló(7), Omkar U. Kawalekar(6), Regina M. Young(6), Keisuke Watanabe(6), Brian Keith(5), Juan J. Rojas(5), Mireia Bachiller(5), Prachi Patel(4), Michael C. Milone(4), Marco Ruella(4), Carmine Carpenito(4), Matthew J. Frigault(4), Ji‐Hyun Lee(4)